Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

Summary

This trial is a multicenter, single-arm, open design designed to evaluate the safety and tolerability of Autologous Tumor Infiltrating Lymphocyte Injection in the treatment of patients with advanced solid tumors, as well as pharmacokinetic profiling and efficacy. The trial consists of two phases: dose-escalation and dose-expansion.

Timeline

Start

2023-02-26

Primary completion

2025-12-30

Completion

2025-12-30

Outcome

Outcome not reported

Stopped (Business): “The study was terminated from a business perspective.”

Drugs

Indications